Bob Bradway, Amgen CEO (Stephen Lam/Reuters)
April 28, 2023 07:22 AM EDT
R&D

Am­gen bows out of PhI­Ib tri­als test­ing bis­pe­cif­ic, fu­sion pro­tein for lu­pus

Amber Tong

In a set­back to the grow­ing field of sys­temic lu­pus ery­the­mato­sus drug de­vel­op­ment, Am­gen is bow­ing out of two Phase IIb tri­als af­ter de­cid­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times